Fujian Wanchen Biotechnology Group Future Growth

Future criteria checks 6/6

Fujian Wanchen Biotechnology Group is forecast to grow earnings and revenue by 75.9% and 26.1% per annum respectively. EPS is expected to grow by 76.5% per annum. Return on equity is forecast to be 30.2% in 3 years.

Key information

75.9%

Earnings growth rate

76.5%

EPS growth rate

Food earnings growth	31.4%
Revenue growth rate	26.1%
Future return on equity	30.2%
Analyst coverage	Low
Last updated	28 Apr 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

SZSE:300972 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	30,054	535	N/A	1,922	1
12/31/2025	23,962	359	N/A	1,356	1
12/31/2024	20,486	190	N/A	384	1
3/31/2024	13,362	-129	1,035	1,270	N/A
12/31/2023	9,294	-83	804	1,023	N/A
9/30/2023	5,091	-46	-320	-65	N/A
6/30/2023	2,564	40	-298	30	N/A
3/31/2023	1,194	76	-256	57	N/A
1/1/2023	549	48	-246	70	N/A
9/30/2022	546	82	-66	128	N/A
6/30/2022	471	38	0	89	N/A
3/31/2022	448	25	6	81	N/A
1/1/2022	435	23	57	99	N/A
9/30/2021	371	4	38	87	N/A
6/30/2021	399	33	66	122	N/A
3/31/2021	417	65	111	157	N/A
12/31/2020	450	96	100	156	N/A
9/30/2020	449	101	115	162	N/A
6/30/2020	460	110	133	171	N/A
3/31/2020	483	130	155	198	N/A
12/31/2019	451	92	138	177	N/A
9/30/2019	442	82	N/A	N/A	N/A
6/30/2019	418	74	114	151	N/A
3/31/2019	358	28	N/A	N/A	N/A
1/1/2019	343	35	-23	102	N/A
9/30/2018	298	15	N/A	N/A	N/A
6/30/2018	258	-3	-123	63	N/A
3/31/2018	265	24	N/A	N/A	N/A
1/1/2018	247	16	N/A	57	N/A
9/30/2017	259	31	N/A	N/A	N/A
6/30/2017	267	46	N/A	100	N/A
3/31/2017	254	52	N/A	N/A	N/A
12/31/2016	220	39	N/A	80	N/A
9/30/2016	189	40	N/A	59	N/A
6/30/2016	157	30	N/A	40	N/A
3/31/2016	157	31	N/A	49	N/A
12/31/2015	157	33	N/A	58	N/A
9/30/2015	149	30	N/A	48	N/A
6/30/2015	160	37	N/A	68	N/A
3/31/2015	145	35	N/A	67	N/A
12/31/2014	130	34	N/A	66	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 300972 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.9%).

Earnings vs Market: 300972 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 300972 is expected to become profitable in the next 3 years.

Revenue vs Market: 300972's revenue (26.1% per year) is forecast to grow faster than the CN market (14.2% per year).

High Growth Revenue: 300972's revenue (26.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 300972's Return on Equity is forecast to be high in 3 years time (30.2%)

Fujian Wanchen Biotechnology Group Future Growth

Future criteria checks 6/6

Key information

Recent future growth updates

Price target decreased by 27% to CN¥28.54

Recent updates

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Fujian Wanchen Biotechnology Group Co., Ltd., Annual General Meeting, May 13, 2024

Price target decreased by 27% to CN¥28.54

New minor risk - Shareholder dilution

Fujian Wanchen Biotechnology Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 23, 2024

New major risk - Share price stability

Third quarter 2023 earnings released: CN¥0.33 loss per share (vs CN¥0.23 profit in 3Q 2022)

Fujian Wanchen Biotechnology Co., Ltd Announces Management Appointments

New major risk - Earnings quality

New major risk - Financial position

Second quarter 2023 earnings released: CN¥0.38 loss per share (vs CN¥0.15 loss in 2Q 2022)

Investor sentiment deteriorates as stock falls 15%

Fujian Wanchen Biotechnology Co., Ltd to Report First Half, 2024 Results on Aug 19, 2023

First quarter 2023 earnings released: EPS: CN¥0.34 (vs CN¥0.16 in 1Q 2022)

Investor sentiment improves as stock rises 23%

Investor sentiment improves as stock rises 32%

Investor sentiment improves as stock rises 17%

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.23 (vs CN¥0.063 loss in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: CN¥0.15 loss per share (vs CN¥0.18 loss in 2Q 2021)

Fujian Wanchen Biotechnology Co., Ltd Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date: 06 June 2022

Fujian Wanchen Biotechnology Co., Ltd Announces Dividend for 2021

Fujian Wanchen Biotechnology Co., Ltd Proposes Final Cash Dividend for 2021

Full year 2021 earnings released: EPS: CN¥0.17 (vs CN¥0.84 in FY 2020)

Third quarter 2021 earnings released: CN¥0.063 loss per share (vs CN¥0.20 profit in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: CN¥0.18 loss per share (vs CN¥0.03 loss in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.22 in 1Q 2020)

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies